WASHINGTON, May 14, 2015 /PRNewswire/ -- Digestive Disease Week®, Booth # 2010 -- EndoChoice's platform of gastrointestinal products and services will be on display during Digestive Disease Week (DDW®), May 17-20 in Washington, D.C. Products from EndoChoice's Imaging, Devices, Diagnostics, and Single-Use specialty areas will be available for hands-on demonstration at EndoChoice's booth throughout the entire week.
The company will also be launching new innovations including Fuse® Full Spectrum Endoscopy® Generation 2, Boa® Polypectomy Snare, Neptune® Injection Needle, and a quality measures program that will simplify the task of tracking key GI procedure measures such as adenoma detection rates (ADR).
"The mission of EndoChoice is to serve the GI caregiver by providing innovative products. Each year, DDW provides us with an opportunity to allow physicians to experience EndoChoice products that we believe will enable them to provide even higher levels of care for their patients," said Mark Gilreath, founder and CEO at EndoChoice.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 16–19, 2015, at the Walter E. Washington Convention Center, Washington, DC. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Based in the Atlanta GA area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®).
EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or Doug.Ladd@endochoice.com
For more information on Fuse:
SOURCE EndoChoice, Inc.